Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy Cancer Patients With Radiologically Positive Axillary Lymph Nodes

Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy in Breast Cancer Patients With Radiologically Positive Axillary Lymph Nodes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01622478

Acronym

VSNBNAC

Enrollment

120

Registered

2012-06-19

Start date

2006-12-31

Completion date

2009-11-30

Last updated

2012-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

sentinel lymph node biopsy, neoadjuvant chemotherapy, breast cancer, locally advanced breast cancer, positive axillary lymph node, negative conversion

Brief summary

Sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) is currently debatable. It is possible that the tumor response to chemotherapy may alter the lymphatic drainage thus causing lower SLN identification rate and higher false negative rate. Further, the response of NAC can be different in each lymph nodes. It is doubtful whether SLNB can accurately predict axillary lymph node (ALN) status after NAC. The aim of this study to determine the identification rate, the false-negative rate, and the accuracy of SLNB after NAC for node positive breast cancer.

Interventions

PROCEDURESentinel lymph node biopsy

Sentinel lymph node biopsy after neoadjuvant chemotherapy for the patients with clinically positive-nodes at presentation

DRUGNeoadjuvant chemotherapy

Neoadjuvant chemotherapy for breast cancer patients with clinically positive-node at initial diagnosis

PROCEDUREcomplete axillary lymph node dissection

Complete axillary lymph node dissection after sentinel node biopsy for estimation of false-negative rate of sentinel node biopsy

PROCEDUREpositron emission tomography and ultrasonogram

Routine evaluation of axillary nodal status using 18-fluorodeoxyglucose positron emission tomography and ultrasonogram before and after chemotherapy

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Advanced breast cancer patients with node-positive proved in preoperative imaging study * ECOG status 0-1

Exclusion criteria

* No previous cancer history * No previous chemotherapy history

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026